Pharmaengine Inc News Today

COSTA MESA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Mr. Jung-Chin (Rongjin) Lin to its board of directors. He is Honorary President of Center Laboratories, Inc. and Chairman of the Board of Lumosa Therapeutics Co., Ltd. and Glac Biotech Co., Ltd. He also serves as a Board member at Adimmune Corp. and BioGend Therapeutics Co., Ltd

Taipei, Nov. 12 (CNA) The latest move by global index provider MSCI Inc. to cut Taiwan's weighting in its major index is expected to have only a minor adverse impact on the local equity market, according to the Financial Supervisory Commission (FSC).

Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care

New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data

PharmaEngine Inc (智擎生技) founder Grace Yeh (葉常菁) has become the Industrial Technology Research Institute’s (ITRI, 工業技術研究院) first female fellow since it started awarding business leaders with fellowships 10 years ago. ITRI chairman Lee Chih-kung (李世光) told the 10th ITRI Laureates award ceremony on Tuesday that Yeh’s induction was significant, because in addition to being the institute’s 50th laureate, she is its first female fellow. Yeh said she was surprise...

NANOBIOTIX Announces First Quarter Operational and Financial Updates Expanded clinical data set supporting tumor agnostic potential of NBTXR3 in presentation of first results in rectal cancer at ASCO-GI 2021 Initiated new combination study evaluating NBTXR3 activated by radiation in combination with chemotherapy in esophageal cancer and reported new preclinical data in immunotherapy at AACR RSM 2021, providing further support for radioenhancer NBTXR3 as a therapeutic combination-agnostic that c...

NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and ...

The agreement provided PharmaEngine exclusive rights to further the development of NBTXR3 in the Asia-Pacific region. Nanobiotix filed a prospectus last year notifying PharmaEngine of a material breach of the terms of the agreement. PharmaEngine denied any breach and asserted certain material breaches of that agreement by Nanobiotix. Pursuant to this termination, Nanobiotix will retain all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. PharmaEngine will re...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 4, 2021--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (PharmaEngine) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in Augu...